February 27, 2024 10:41 AM EST

Roche is 'evaluating potential options' for IPF drug Esbriet as generics gain traction

Kyle LaHucik

Senior Reporter

Roche is looking to offload its idiopathic pulmonary fibrosis drug Esbriet as more patients with the fatal lung disease opt for generic versions and Big …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche is 'evaluating potential options' for IPF drug Esbriet as generics gain traction

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Roche is 'e­val­u­at­ing po­ten­tial op­tion­s' for IPF drug Es­bri­et as gener­ics gain trac­tion

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Roche is 'evaluating potential options' for IPF drug Esbriet as generics gain traction

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?